<SEC-DOCUMENT>0001193125-24-138893.txt : 20240515
<SEC-HEADER>0001193125-24-138893.hdr.sgml : 20240515
<ACCEPTANCE-DATETIME>20240515074054
ACCESSION NUMBER:		0001193125-24-138893
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20240513
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240515
DATE AS OF CHANGE:		20240515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Spyre Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001636282
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				464312787
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37722
		FILM NUMBER:		24947181

	BUSINESS ADDRESS:	
		STREET 1:		221 CRESCENT STREET
		STREET 2:		BUILDING 23, SUITE 105
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
		BUSINESS PHONE:		6176515940

	MAIL ADDRESS:	
		STREET 1:		221 CRESCENT STREET
		STREET 2:		BUILDING 23, SUITE 105
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Aeglea BioTherapeutics, Inc.
		DATE OF NAME CHANGE:	20150311
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d839821d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:syre="http://spyre.com/20240513" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-657">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2024-05-13_to_2024-05-13">0001636282</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_CurrentFiscalYearEndDate_duration_2024-05-13_to_2024-05-13" name="dei:CurrentFiscalYearEndDate" contextRef="duration_2024-05-13_to_2024-05-13">--12-31</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="syre-20240513.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2024-05-13_to_2024-05-13"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-05-13</xbrli:startDate> <xbrli:endDate>2024-05-13</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-669">8-K</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of The Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of Earliest Event Reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2024-05-13_to_2024-05-13" format="ixt:datemonthdayyearen" id="ixv-670">May 13, 2024</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-671">SPYRE THERAPEUTICS, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2024-05-13_to_2024-05-13" format="ixt-sec:stateprovnameen" id="ixv-672">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-673">001-37722</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-674">46-4312787</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or Other Jurisdiction<br/>of Incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(IRS Employer<br/>Identification No.)</span></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-675">221 Crescent Street</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-676">Building 23</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine3" contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-677">Suite 105</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-678">Waltham</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2024-05-13_to_2024-05-13" format="ixt-sec:stateprovnameen" id="ixv-679">Massachusetts</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-680">02453</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-681">617</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-682">651-5940</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2024-05-13_to_2024-05-13" format="ixt-sec:boolballotbox" id="ixv-683">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2024-05-13_to_2024-05-13" format="ixt-sec:boolballotbox" id="ixv-684">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2024-05-13_to_2024-05-13" format="ixt-sec:boolballotbox" id="ixv-685">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2024-05-13_to_2024-05-13" format="ixt-sec:boolballotbox" id="ixv-686">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-687">Common stock, $0.0001 Par Value</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-688">SYRE</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2024-05-13_to_2024-05-13" format="ixt-sec:exchnameen" id="ixv-689">The Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2024-05-13_to_2024-05-13" format="ixt-sec:boolballotbox" id="ixv-690">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;1.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&#160;14, 2024, Spyre Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221;), and Paragon Therapeutics, Inc., a Delaware corporation (&#8220;Paragon&#8221;), entered into (i)&#160;a license agreement (the &#8220;SPY001 License Agreement&#8221;), pursuant to which Paragon granted the Company a royalty-bearing, world-wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain antibodies and products targeting &#945;4&#223;7 integrin and (ii)&#160;a license agreement (the &#8220;SPY002 License Agreement&#8221; and, together with the SPY001 License Agreement, the &#8220;License Agreements&#8221;), pursuant to which Paragon granted the Company a royalty-bearing, world-wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain licensed antibodies and products targeting TL1A, respectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of each License Agreement, the Company is obligated to pay Paragon up to $22.0&#160;million based on specific development, regulatory and clinical milestones for each licensed research program, including a $1.5&#160;million fee for nomination of a development candidate, as applicable, and a further milestone payment of $2.5&#160;million upon the first dosing of a human patient in a Phase 1 trial. In addition, the following summarizes other key terms of each License Agreement: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Paragon will provide the Company with an exclusive license to its patents covering the related antibody, the method of use and its method of manufacture. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Paragon will not conduct any new campaigns that generate anti-&#945;4&#223;7 or anti-TL1A monospecific antibodies for at least 5 years. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Company will pay Paragon a low single-digit percentage royalty for single antibody products and a mid single-digit percentage royalty for products containing more than one antibody from Paragon. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">There is a royalty step-down of 1/3rd if there is no Paragon patent in effect during the royalty term. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The royalty term ends on the later of (i)&#160;the <span style="white-space:nowrap"><span style="white-space:nowrap">last-to-expire</span></span> licensed patent or Company patent directed to a derived antibody or (ii) 12 years from the date of first sale of a Company product. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Agreement may be terminated on 60 days&#8217; notice by the Company; on material breach without cure; and to the extent permitted by law, on a party&#8217;s insolvency or bankruptcy. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">With respect to the SPY002 License Agreement only, on a product by product basis, the Company will pay Paragon sublicensing fees of up to approximately $20&#160;million upon the achievement of mostly commercial milestones. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on May&#160;14, 2024, the Company, Paragon and Parapyre Holding LLC entered into a second amended and restated antibody discovery and option agreement (the &#8220;Second AR ADOA&#8221;) that amends and restates that certain amended and restated antibody discovery and option agreement, dated September&#160;29, 2023, by and between Paragon, Parapyre and Spyre Therapeutics, LLC, in order to, among other things, (i)&#160;replace the Company&#8217;s subsidiary with the Company as a party to the agreement and (ii)&#160;amend certain terms related to the <span style="white-space:nowrap">IL-23</span> research program, including without limitation, (a)&#160;establishing an <span style="white-space:nowrap">IL-23</span> antibody selection process pursuant to which the Company and Paragon shall alternate in turn to select a project antibody to be included and excluded, respectively, from the Company&#8217;s rights under its option to license certain intellectual property rights related to <span style="white-space:nowrap">IL-23</span> from Paragon until all project antibodies under the <span style="white-space:nowrap">IL-23</span> research program have been selected; (b)&#160;reducing the development costs invoiced to the Company for the <span style="white-space:nowrap">IL-23</span> research program incurred from and after April&#160;1, 2024 through completion of the <span style="white-space:nowrap">IL-23</span> antibody selection process by 50%; (c) requiring Paragon to reimburse the Company for 50% of the development costs for the <span style="white-space:nowrap">IL-23</span> research program incurred prior to April&#160;1, 2024; provided, that Paragon receives rights to at least one <span style="white-space:nowrap">IL-23</span> project antibody following completion of the <span style="white-space:nowrap">IL-23</span> antibody selection process; (d)&#160;obligating the Company to exercise its option to license the intellectual property rights to <span style="white-space:nowrap">IL-23</span> project antibodies and technology following the completion of the <span style="white-space:nowrap">IL-23</span> antibody selection process; and (e)&#160;establishing a license agreement term sheet for the <span style="white-space:nowrap">IL-23</span> research program with substantially similar milestone payment terms and royalty payment terms as the SPY001 License Agreement. </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing descriptions of the material terms of the SPY001 License Agreement, the SPY002 License Agreement and the Second AR ADOA do not purport to be complete and is each qualified in its entirety by reference to the complete text of the SPY001 License Agreement, the SPY002 License Agreement and the Second AR ADOA, respectively; copies of which the Company intends to file, with confidential terms redacted, with the Securities and Exchange Commission as exhibits to the Company&#8217;s Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> for the quarterly period ended June&#160;30, 2024. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;5.02</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Appointment of Director </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&#160;14, 2024, the board of directors (the &#8220;Board&#8221;) of the Company appointed Sandra Milligan, M.D., J.D. as a Class&#160;III director of the Company and as a member of the Board&#8217;s compensation committee and nominating and corporate governance committee, effective immediately. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&#160;Milligan, age 50, has served as President of Aspira Women&#8217;s Health, a <span style="white-space:nowrap">bio-analytical</span> based women&#8217;s health company focused on the development of gynecologic disease diagnostic tools, since April 2024. Previously, from 2020 to 2024, Dr.&#160;Milligan served as the Head of Research and Development of Organon&#160;&amp; Co. and, from 2015 to 2020, as Merck&#160;&amp; Co.&#8217;s Senior Vice President and Head of Global Regulatory Affairs and Clinical Safety. Previously, from 2012 to 2015, she served as Vice President of Product Development Regulatory for Genentech, Inc., and, from 2002 to 2012, she was at Amgen Inc. in positions of increasing responsibility across legal and regulatory affairs functions. Dr.&#160;Milligan served in the United States Army Medical Corps from 1987 to 1994. Dr.&#160;Milligan was on the Board of Directors of the Drug Information Association, or DIA, from 2011 to 2017, including serving as chair, and is now a DIA fellow. Dr.&#160;Milligan has served as a member of the board of directors of Gossamer Bio, Inc. (Nasdaq: GOSS) since June 2021. Dr.&#160;Milligan received a B.S. in Biology and a B.A. in Psychology from the University of California, Irvine. Additionally, she is a graduate of George Washington University School of Medicine and received a J.D. from the Georgetown University Law Center. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with her appointment to the Board, Dr.&#160;Milligan is expected to enter into the Company&#8217;s standard form of indemnification agreement, a copy of which was filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on February&#160;5, 2024. Dr.&#160;Milligan will receive cash compensation in accordance with the Company&#8217;s <span style="white-space:nowrap">non-employee</span> director cash and equity compensation program (the &#8220;Program&#8221;) as generally described under the <span style="white-space:nowrap">&#8220;Non-Employee</span> Director Compensation Arrangements&#8221; section in the Proxy Statement (as defined below) and an option to purchase a number of shares of the Company&#8217;s common stock, par value $0.0001 per share (&#8220;Common Stock&#8221;), with an aggregate grant date value of $700,000 under the Company&#8217;s 2016 Equity Incentive Plan, as amended and restated, in accordance with the Program, with an exercise price per share equal to the closing price of Common Stock on the Nasdaq Stock Market on the date of the grant and a <span style="white-space:nowrap">10-year</span> term. This option will vest and become exercisable in 36 equal monthly installments beginning on the date of the grant until such time as the option is 100% vested, subject to Dr.&#160;Milligan&#8217;s continued service to the Company through each applicable vesting date. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no family relationships between Dr.&#160;Milligan and any of the executive officers or directors of the Company. There are no arrangements or understandings between Dr.&#160;Milligan and any other person pursuant to which she was appointed as a director of the Company. Dr.&#160;Milligan is not a party to any transaction required to be disclosed pursuant to Item 404(a) of Regulation <span style="white-space:nowrap">S-K.</span> </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;5.03</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&#160;14, 2024, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment (the &#8220;Certificate of Amendment&#8221;) to the Company&#8217;s Amended and Restated Certificate of Incorporation to extend the exculpation provisions contained therein to certain officers. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&#160;14, 2024, the Company filed with the Secretary of State of the State of Delaware a Second Amended and Restated Certificate of Incorporation (the &#8220;Certificate of Incorporation&#8221;) that only restates and integrates and does not further amend the provisions of the Amended and Restated Certificate of Incorporation, as amended by the Certificate of Amendment. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing descriptions of the Certificate of Amendment and the Certificate of Incorporation do not purport to be complete and are subject to and qualified in their entirety by reference to the Certificate of Amendment and the Certificate of Incorporation, copies of which are attached hereto as Exhibit 3.1 and Exhibit 3.2 and are incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;5.07</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Submission of Matters to a Vote of Security Holders. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&#160;13, 2024, the Company held its Annual Meeting of Stockholders (the &#8220;Annual Meeting&#8221;). The proposals considered at the Annual Meeting are described in the Company&#8217;s definitive proxy statement filed with the SEC on April&#160;1, 2024 (the &#8220;Proxy Statement&#8221;). The final voting results were as follows: </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Proposal No.&#160;1 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s stockholders elected two Class&#160;II directors, Jeffrey W. Albers and Tomas Kiselak, each to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:96%;border:0;margin:0 auto">


<tr>

<td style="width:24%"/>

<td style="vertical-align:bottom"/>
<td style="width:24%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:25%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:24%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Nominees</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">For</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Withheld</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="white-space:nowrap">Broker&#160;Non-Votes</span></p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey W. Albers</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">22,252,788</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">5,909,047</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">945,466</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tomas Kiselak</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">22,016,240</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">6,145,595</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">945,466</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Proposal No.&#160;2 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s stockholders approved, on a <span style="white-space:nowrap">non-binding,</span> advisory basis, the compensation of the Company&#8217;s named executive officers. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:24%"/>

<td style="vertical-align:bottom"/>
<td style="width:24%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:25%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:24%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">For</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Against</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Abstain</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="white-space:nowrap">Broker&#160;Non-Votes</span></p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom" align="center">17,465,368</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">10,689,515</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">6,952</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">945,466</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Proposal No.&#160;3 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company&#8217;s independent registered public accounting firm for the year ending December&#160;31, 2024. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:24%"/>

<td style="vertical-align:bottom"/>
<td style="width:24%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:25%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:24%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">For</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Against</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Abstain</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Broker <span style="white-space:nowrap">Non-Votes</span></p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom" align="center">29,096,079</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">10,509</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">713</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">0</td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Proposal No. 4a </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s stockholders approved the issuance of Common Stock upon conversion of the Company&#8217;s Series B <span style="white-space:nowrap">Non-Voting</span> Convertible Preferred Stock, par value $0.0001 per share (&#8220;Series B Preferred Stock&#8221;), issued in December 2023. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:24%"/>

<td style="vertical-align:bottom"/>
<td style="width:24%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:25%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:24%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">For</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Against</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Abstain</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Broker <span style="white-space:nowrap">Non-Votes</span></p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom" align="center">28,136,379</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">18,517</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">6,939</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">945,466</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Proposal No. 4b </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s stockholders approved the issuance of Common Stock upon conversion of the Company&#8217;s Series B Preferred Stock issued in March 2024. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:24%"/>

<td style="vertical-align:bottom"/>
<td style="width:24%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:25%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:24%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">For</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Against</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Abstain</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Broker <span style="white-space:nowrap">Non-Votes</span></p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom" align="center">28,136,102</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">18,675</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">7,058</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">945,466</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Proposal No.&#160;5 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s stockholders approved an amendment to the Company&#8217;s Amended and Restated Certificate of Incorporation to reflect Delaware law provisions regarding officer exculpation. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:24%"/>

<td style="vertical-align:bottom"/>
<td style="width:24%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:25%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:24%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">For</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Against</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Abstain</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Broker <span style="white-space:nowrap">Non-Votes</span></p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom" align="center">26,588,617</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">1,572,985</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">233</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">945,466</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Proposal No.&#160;6 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s stockholders approved an adjournment of the Annual Meeting, if necessary or appropriate, to solicit additional proxies. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:24%"/>

<td style="vertical-align:bottom"/>
<td style="width:24%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:25%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:24%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">For</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Against</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Abstain</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Broker <span style="white-space:nowrap">Non-Votes</span></p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom" align="center">19,695,462</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">8,458,691</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">7,682</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">945,466</td></tr>
</table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;7.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the approvals of Proposal Nos. 4a and 4b and the effectiveness of the conversion of the Company&#8217;s Series B Preferred Stock, the Company is expected to have approximately 65.2&#160;million shares of Common Stock issued and outstanding on a pro forma basis, which gives effect to the full conversion of the Series B Preferred Stock as of the date of the Annual Meeting, without regard to beneficial ownership limitations that may limit the ability of certain holders of Series B Preferred Stock to convert such shares to Common Stock as such time, and assumes the conversion of all of the Company&#8217;s outstanding Series A <span style="white-space:nowrap">Non-Voting</span> Convertible Preferred Stock, par value $0.0001 per share. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&#160;15, 2024, the Company issued a press release announcing the appointment of Dr.&#160;Milligan to the Board. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in Item 7.01 of this Current Report on Form <span style="white-space:nowrap">8-K,</span> including the information in the press release attached as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K,</span> is furnished pursuant to Item 7.01 of Form <span style="white-space:nowrap">8-K</span> </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and shall not be deemed &#8220;filed&#8221; for the purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this Current Report on Form <span style="white-space:nowrap">8-K,</span> including the information in the press release attached as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K,</span> shall not be deemed to be incorporated by reference in the filings of the Company under the Securities Act of 1933, as amended. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d)&#160;Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:5%"/>
<td style="width:92%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">3.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d839821dex31.htm">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company, effective as of May&#160;14, 2024. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">3.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d839821dex32.htm">Second Amended and Restated Certificate of Incorporation of the Company, effective as of May&#160;14, 2024. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d839821dex991.htm">Press Release, dated May&#160;15, 2024. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3">Date: May&#160;15, 2024</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">SPYRE THERAPEUTICS, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Cameron Turtle</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cameron Turtle</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</p></td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>d839821dex31.htm
<DESCRIPTION>EX-3.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT TO THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF SPYRE THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Spyre Therapeutics, Inc. (the &#147;<B>Corporation</B>&#148;), a corporation organized and existing under and by virtue of the provisions of
the General Corporation Law of the State of Delaware (the &#147;<B>General Corporation Law</B>&#148;), does hereby certify: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1. The
current name of the Corporation is Spyre Therapeutics, Inc. The Corporation was first formed on December&nbsp;16, 2013 under the name Aeglea BioTherapeutics Holdings, LLC, a Delaware limited liability company. Aeglea BioTherapeutics Holdings, LLC
converted into Aeglea BioTherapeutics, Inc. on March&nbsp;10, 2015. The date of filing of the original Certificate of Incorporation of Aeglea BioTherapeutics, Inc. with the Secretary of State was March&nbsp;10, 2015 under the name Aeglea
BioTherapeutics, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. The Amended and Restated Certificate of Incorporation of the Corporation was filed with the Secretary of State
of the State of Delaware on November&nbsp;27, 2023 (the &#147;<B>Certificate of Incorporation</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3. The amendments to the
existing Certificate of Incorporation being effected hereby are to amend and restate in its entirety Article VII: Director Liability of the Certificate of Incorporation to read as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#147;<B>ARTICLE VII: DIRECTOR AND OFFICER LIABILITY</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. </B><B><U>Limitation of Liability</U></B>. To the fullest extent permitted by law, no director or officer of the Corporation shall be personally liable
for monetary damages for breach of fiduciary duty as a director or officer. Without limiting the effect of the preceding sentence, if the Delaware General Corporation Law is hereafter amended to authorize the further elimination or limitation of the
liability of a director or officer, then the liability of a director or officer of the Corporation shall be eliminated or limited to the fullest extent permitted by the Delaware General Corporation Law, as so amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. </B><B><U>Change in Rights</U></B>. Neither any amendment nor repeal of this Article VII, nor the adoption of any provision of this Certificate of
Incorporation inconsistent with this Article VII, shall eliminate, reduce or otherwise adversely affect any limitation on the personal liability of a director or officer of the Corporation existing at the time of such amendment, repeal or adoption
of such an inconsistent provision.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4. All other provisions of the Certificate of Incorporation shall remain in full force and
effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5. The amendment of the Certificate of Incorporation herein certified has been duly adopted in accordance with the provisions of
242 of the General Corporation Law. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Corporation has caused this Certificate of Amendment to be
executed by the undersigned authorized officer of the Corporation as of this 14<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> day of May, 2024. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Cameron Turtle</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Cameron Turtle</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>3
<FILENAME>d839821dex32.htm
<DESCRIPTION>EX-3.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPYRE THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Spyre Therapeutics, Inc. (the &#147;<B>Corporation</B>&#148;), a corporation organized and existing under and by virtue of the provisions of
the General Corporation Law of the State of Delaware (the &#147;<B>General Corporation Law</B>&#148;), does hereby certify as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.
The current name of the Corporation is Spyre Therapeutics, Inc. The Corporation was first formed on December&nbsp;16, 2013 under the name Aeglea BioTherapeutics Holdings, LLC, a Delaware limited liability company. Aeglea BioTherapeutics Holdings,
LLC converted into Aeglea BioTherapeutics, Inc. on March&nbsp;10, 2015. The date of filing of the original Certificate of Incorporation of Aeglea BioTherapeutics, Inc. with the Secretary of State was March&nbsp;10, 2015 under the name Aeglea
BioTherapeutics, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. The Second Amended and Restated Certificate of Incorporation of the Corporation attached hereto as <U>Exhibit
&#147;A&#148;</U>, which is incorporated herein by this reference, only restates and integrates and does not further amend the provisions of the Amended and Restated Certificate of Incorporation of the Corporation as theretofore amended or
supplemented and there is no discrepancy between those provisions and the provisions of the Second Amended and Restated Certificate of Incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3. The Second Amended and Restated Certificate of Incorporation has been duly adopted by the Board of Directors of the Corporation in
accordance with Section&nbsp;245 of the Delaware General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, this Corporation has caused this
Amended and Restated Certificate of Incorporation to be signed by a duly authorized officer of this Corporation on this 14<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> day of&nbsp;May, 2024. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Cameron Turtle</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Cameron Turtle</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT &#147;A&#148; </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPYRE THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I: NAME </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The name of the
corporation is Spyre Therapeutics, Inc. (the &#147;<B><I>Corporation</I></B>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II: AGENT FOR SERVICE OF PROCESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The address of the Corporation&#146;s registered office in the State of Delaware is 1521 Concord Pike Suite 201, City of Wilmington, County of New Castle,
Delaware 19803. The name of the registered agent of the Corporation at that address is Corporate Creations Network Inc. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III:
PURPOSE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General
Corporation Law of the State of Delaware. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV: AUTHORIZED STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.</B><B></B><B>&nbsp;<U>Total Authorized</U></B><B>.</B>&nbsp;The total number of shares of all classes of stock that the Corporation has authority to
issue is Four Hundred and Ten Million (410,000,000) shares, consisting of two classes: Four Hundred Million (400,000,000) shares of Common Stock, $0.0001 par value per share (&#147;<B><I>Common Stock</I></B>&#148;), and Ten Million (10,000,000)
shares of Preferred Stock, $0.0001 par value per share (&#147;<B><I>Preferred Stock</I></B>&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.&nbsp;<U>Designation of Additional
Series</U>.</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.1. The Board of Directors of the Corporation (the &#147;<B><I>Board</I></B>&#148;) is authorized, subject to any limitations prescribed
by the law of the State of Delaware, to provide for the issuance of the shares of Preferred Stock in one or more series, and, by filing a Certificate of Designation pursuant to the applicable law of the State of Delaware, to establish from time to
time the number of shares to be included in each such series, to fix the designation, vesting, powers, preferences and relative, participating, optional or other rights, if any, of the shares of each such series and any qualifications, limitations
or restrictions thereof, and to increase (but not above the total number of authorized shares of the class) or decrease (but not below the number of shares of such series then outstanding) the number of shares of any such series. The number of
authorized shares of Preferred Stock may also be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders <FONT STYLE="white-space:nowrap">of&nbsp;two-thirds&nbsp;of</FONT> the
voting power of all then outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, without a vote of the holders of the Preferred Stock, unless a vote of any other holders is required pursuant to
a Certificate or Certificates establishing a series of Preferred Stock;<I>&nbsp;<U>provided</U></I>, that <FONT STYLE="white-space:nowrap">if&nbsp;two-thirds&nbsp;of</FONT> the Whole Board has approved such increase or decrease of the number of
authorized shares of Preferred Stock, then only the affirmative vote of the holders of a majority of the voting power of all of the then outstanding shares of the capital stock of the Corporation entitled to vote generally in the election of
directors, voting together as a single class, without a vote of the holders of the Preferred Stock (unless a vote of any other holders is required pursuant to a Certificate or Certificates establishing a series of Preferred Stock), shall be required
to effect such increase or decrease. For purposes of this Certificate of Incorporation, the term &#147;<B><I>Whole Board</I></B>&#148; shall mean the total number of authorized directors whether or not there exist any vacancies in previously
authorized directorships. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.2 Except as otherwise expressly provided in any Certificate of Designation designating any series of
Preferred Stock pursuant to the foregoing provisions of this Article IV, any new series of Preferred Stock may be designated, fixed and determined as provided herein by the Board without approval of the holders of Common Stock or the holders of
Preferred Stock, or any series thereof, and any such new series may have powers, preferences and rights, including, without limitation, voting rights, dividend rights, liquidation rights, redemption rights and conversion rights, senior to, junior to
or pari passu with the rights of the Common Stock, the Preferred Stock or any future class or series of Preferred Stock or Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.3 Each
outstanding share of Common Stock shall entitle the holder thereof to one vote on each matter properly submitted to the stockholders of the Corporation for their vote;<I>&nbsp;<U>provided</U></I><I>,</I><I></I><I>&nbsp;<U>however</U></I>, that,
except as otherwise required by law, holders of Common Stock shall not be entitled to vote on any amendment to this Certificate of Incorporation (including any Certificate of Designation relating to any series of Preferred Stock) that relates solely
to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more other such series, to vote thereon pursuant to this
Certificate of Incorporation (including any Certificate of Designation relating to any series of Preferred Stock). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V: AMENDMENT
OF BYLAWS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board shall have the power to adopt, amend or repeal the Bylaws of the Corporation. Any adoption, amendment or repeal of the Bylaws of
the Corporation by the Board shall require the approval of a majority of the Whole Board. For purposes of this Certificate of Incorporation, the term &#147;<B><I>Whole Board</I></B>&#148; shall mean the total number of authorized directors whether
or not there exist any vacancies in previously authorized directorships. The stockholders shall also have power to adopt, amend or repeal the Bylaws of the Corporation;<I>&nbsp;<U>provided</U></I>,<I>&nbsp;<U>however</U></I>, that in addition to any
vote of the holders of any class or series of stock of the Corporation required by law or by this Certificate of Incorporation (including any Preferred Stock issued pursuant to a Certificate of Designation), the affirmative vote of the holders of at
<FONT STYLE="white-space:nowrap">least&nbsp;two-thirds&nbsp;of</FONT> the voting power of all of the then outstanding shares of the capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single
class, shall be required to adopt, amend or repeal any provision of the Bylaws;<I>&nbsp;<U>provided</U> <U>further</U></I>, that <FONT STYLE="white-space:nowrap">if&nbsp;two-thirds&nbsp;of</FONT> the Whole Board has approved such adoption, amendment
or repeal of any provisions of the Bylaws, then only the affirmative vote of the holders of a majority of the voting power of all of the then-outstanding shares of the capital stock of the Corporation entitled to vote generally in the election of
directors, voting together as a single class, shall be required to adopt, amend or repeal any provision of the Bylaws. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI:
MATTERS RELATING TO THE BOARD OF DIRECTORS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.</B><B></B><B>&nbsp;<U>Director Powers</U></B>. The conduct of the affairs of the Corporation shall
be managed by or under the direction of the Board. In addition to the powers and authority expressly conferred upon them by statute or by this Certificate of Incorporation or the Bylaws of the Corporation, the directors are hereby empowered to
exercise all such powers and do all such acts and things as may be exercised or done by the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.</B><B></B><B>&nbsp;<U>Number of
Directors</U></B>. Subject to the rights of the holders of any series of Preferred Stock to elect additional directors under specified circumstances, the number of directors shall be fixed from time to time exclusively by resolution adopted by a
majority of the Whole Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.</B><B></B><B>&nbsp;<U>Classified Board</U></B>. Subject to the rights of the holders of any series of Preferred Stock
to elect additional directors under specified circumstances, the directors shall be divided, with respect to the time for which they severally hold office, into three classes designated as Class&nbsp;I, Class&nbsp;II and Class&nbsp;III, respectively
(the &#147;<B><I>Classified Board</I></B>&#148;). The Board may assign members of the Board already in office to the Classified Board, which assignments shall become effective at the same time the Classified Board becomes effective. Directors shall
be assigned to each class in accordance with a resolution or resolutions adopted by the Board, with the number of directors in each class to be divided as nearly equal as reasonably possible. The initial term of office of the Class&nbsp;I directors
shall expire at the Corporation&#146;s first annual meeting of stockholders following the closing of the Corporation&#146;s initial public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended,
relating to the offer and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sale of Common Stock to the public (the &#147;<B><I>Initial Public Offering</I></B>&#148;), the initial term of office of the Class&nbsp;II directors shall expire at the Corporation&#146;s second
annual meeting of stockholders following the closing of the Initial Public Offering and the initial term of office of the Class&nbsp;III directors shall expire at the Corporation&#146;s third annual meeting of stockholders following the closing of
the Initial Public Offering. At each annual meeting of stockholders following the closing of the Initial Public Offering, directors elected to succeed those directors of the class whose terms then expire shall be elected for a term of office to
expire at the third succeeding annual meeting of stockholders after their election. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.</B><B></B><B>&nbsp;<U>Term and Removal</U></B>. Each director
shall hold office until such director&#146;s successor is elected and qualified, or until such director&#146;s earlier death, resignation or removal. Any director may resign at any time upon notice to the Corporation given in writing or by any
electronic transmission permitted in the Corporation&#146;s Bylaws. Subject to the rights of the holders of any series of Preferred Stock, no director may be removed except for cause and only by the affirmative vote of the holders of at <FONT
STYLE="white-space:nowrap">least&nbsp;two-thirds&nbsp;of</FONT> the voting power of the then-outstanding shares of capital stock of the Corporation then entitled to vote at an election of directors voting together as a single class. In the event of
any increase or decrease in the authorized number of directors, (a)&nbsp;each director then serving as such shall nevertheless continue as a director of the class of which he or she is a member and (b)&nbsp;the newly created or eliminated
directorships resulting from such increase or decrease shall be apportioned by the Board among the classes of directors so as to ensure that no one class has more than one director more than any other class. To the extent possible, consistent with
the foregoing rule, any newly created directorships shall be added to those classes whose terms of office are to expire at the latest dates following such allocation, and any newly eliminated directorships shall be subtracted from those classes
whose terms of office are to expire at the earliest dates following such allocation, unless otherwise provided from time to time by resolution adopted by the Board. No decrease in the authorized number of directors shall shorten the term of any
incumbent director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.</B><B></B><B>&nbsp;<U>Board Vacancies</U></B>. Subject to the rights of the holders of any series of Preferred Stock, any
vacancy occurring in the Board for any cause, and any newly created directorship resulting from any increase in the authorized number of directors, shall, unless (a)&nbsp;the Board determines by resolution that any such vacancies or newly created
directorships shall be filled by the stockholders or (b)&nbsp;as otherwise provided by law, be filled only by the affirmative vote of a majority of the directors then in office, although less than a quorum, or by a sole remaining director, and not
by the stockholders. Any director elected in accordance with the preceding sentence shall hold office for a term expiring at the annual meeting of stockholders at which the term of office of the class to which the director has been assigned expires
or until such director&#146;s successor shall have been duly elected and qualified, or until such director&#146;s earlier death, resignation or removal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.</B><B></B><B>&nbsp;<U>Vote by Ballot</U></B>. Election of directors need not be by written ballot unless the Bylaws of the Corporation shall so provide.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII: DIRECTOR AND OFFICER LIABILITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.</B><B></B><B>&nbsp;<U>Limitation of Liability</U></B>. To the fullest extent permitted by law, no director or officer of the Corporation shall be
personally liable for monetary damages for breach of fiduciary duty as a director or officer. Without limiting the effect of the preceding sentence, if the Delaware General Corporation Law is hereafter amended to authorize the further elimination or
limitation of the liability of a director or officer, then the liability of a director or officer of the Corporation shall be eliminated or limited to the fullest extent permitted by the Delaware General Corporation Law, as so amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.</B><B></B><B>&nbsp;<U>Change in Rights</U></B>. Neither any amendment nor repeal of this Article VII, nor the adoption of any provision of this
Certificate of Incorporation inconsistent with this Article VII, shall eliminate, reduce or otherwise adversely affect any limitation on the personal liability of a director or officer of the Corporation existing at the time of such amendment,
repeal or adoption of such an inconsistent provision. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VIII: MATTERS RELATING TO STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.</B><B></B><B>&nbsp;<U>No Action by Written Consent of Stockholders</U></B>. Subject to the rights of any series of Preferred Stock, no action shall be
taken by the stockholders of the Corporation except at a duly called annual or special meeting of stockholders and no action shall be taken by the stockholders by written consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.</B><B></B><B>&nbsp;<U>Special Meeting of Stockholders</U></B><B>.</B><B></B>&nbsp;Special meetings of the stockholders of the Corporation may be called
only by the Chairperson of the Board, the Chief Executive Officer, the President or the Board acting pursuant to a resolution adopted by a majority of the Whole Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.</B><B></B><B>&nbsp;<U>Advance Notice of Stockholder Nominations and Business Transacted at Special Meetings</U></B>. Advance notice of stockholder
nominations for the election of directors of the Corporation and of business to be brought by stockholders before any meeting of stockholders of the Corporation shall be given in the manner provided in the Bylaws of the Corporation. Business
transacted at special meetings of stockholders shall be confined to the purpose or purposes stated in the notice of meeting. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE
IX: CHOICE OF FORUM </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery in the State of
Delaware shall be the sole and exclusive forum for any stockholder (including a beneficial owner) to bring (i)&nbsp;any derivative action or proceeding brought on behalf of the Corporation, (ii)&nbsp;any action asserting a claim of breach of
fiduciary duty owed by, or other wrongdoing by, any director, officer or other employee of the Corporation to the Corporation or the Corporation&#146;s stockholders, (iii)&nbsp;any action asserting a claim against the Corporation, its directors,
officers or employees arising pursuant to any provision of the Delaware General Corporation Law or the Corporation&#146;s certificate of incorporation or bylaws or (iv)&nbsp;any action asserting a claim against the Corporation, its directors,
officers or employees governed by the internal affairs doctrine, except for, as to each of (i)&nbsp;through (iv) above, any claim as to which the Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of
the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than the
Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction. If any provision or provisions of this&nbsp;Article IX&nbsp;shall be held to be invalid, illegal or unenforceable as applied to any person or entity or
circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this&nbsp;Article IX&nbsp;(including,
without limitation, each portion of any sentence of this&nbsp;Article IX&nbsp;containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) and the application of such
provision to other persons or entities and circumstances shall not in any way be affected or impaired thereby. Any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the Corporation shall be deemed to have
notice of and to have consented to the provisions of this&nbsp;Article IX. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE X: AMENDMENT OF CERTIFICATE OF INCORPORATION
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any provision of this Certificate of Incorporation becomes or is declared on any ground by a court of competent jurisdiction to be illegal,
unenforceable or void, portions of such provision, or such provision in its entirety, to the extent necessary, shall be severed from this Certificate of Incorporation, and the court will replace such illegal, void or unenforceable provision of this
Certificate of Incorporation with a valid and enforceable provision that most accurately reflects the Corporation&#146;s intent, in order to achieve, to the maximum extent possible, the same economic, business and other purposes of the illegal, void
or unenforceable provision. The balance of this Certificate of Incorporation shall be enforceable in accordance with its terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Corporation reserves
the right to amend or repeal any provision contained in this Certificate of Incorporation in the manner prescribed by the laws of the State of Delaware and all rights conferred upon stockholders are granted subject to this
reservation;<I>&nbsp;<U>provided</U></I>,<I>&nbsp;<U>however</U></I>, that, notwithstanding any other provision of this Certificate of Incorporation or any provision of law that might otherwise permit a lesser vote or no vote, but in addition to any
vote of the holders of any class or series of the stock of the Corporation required by law or by this Certificate of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Incorporation, the affirmative vote of the holders of at <FONT STYLE="white-space:nowrap">least&nbsp;two-thirds&nbsp;of</FONT> the voting power of all of the then-outstanding shares of the
capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required to amend or repeal any provision of this Certificate of Incorporation; provided, further, that <FONT
STYLE="white-space:nowrap">if&nbsp;two-thirds&nbsp;of</FONT> the Whole Board has approved such amendment or repeal of any provisions of this Certificate of Incorporation, then only the affirmative vote of the holders of at least a majority of the
voting power of all of the then-outstanding shares of the capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required to amend or repeal such provisions of this
Certificate of Incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>* * * * * * * * * * * </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>d839821dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g839821dsp17.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr.&nbsp;Sandra Milligan to its Board of
Directors </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WALTHAM, Mass., May 15, 2024 (PR NEWSWIRE)&#151;Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the &#147;Company&#148; or &#147;Spyre&#148;), a
development-stage biotechnology company advancing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> antibody engineering, rational therapeutic combinations, and precision medicine approaches for the
treatment of Inflammatory Bowel Disease (&#147;IBD&#148;), today announced the appointment of Sandra Milligan, M.D., J.D., President of Aspira Women&#146;s Health, to its Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;With a distinguished career spanning leadership roles at large and small biopharmaceutical companies, Dr.&nbsp;Milligan brings deep expertise in
clinical development and regulatory affairs, including within IBD, that will be invaluable as we execute on our strategy to deliver novel therapies that improve both efficacy and convenience compared to today&#146;s standard of care,&#148; said
Cameron Turtle, DPhil, Chief Executive Officer of Spyre. &#147;We are excited to incorporate her guidance as we progress our novel antibody therapies targeting &#945;4<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>7 and TL1A into clinical studies in
the upcoming months.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to her current role at Aspira, Dr.&nbsp;Milligan served as the Head of Research and Development of Organon&nbsp;&amp;
Co. Previously, she served in key executive positions, including Senior Vice President and Head of Global Regulatory Affairs and Clinical Safety at Merck; Vice President of Product Development Regulatory at Genentech, Inc.; and important roles
across legal and regulatory affairs at Amgen Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;As a physician, Spyre&#146;s commitment to scientific excellence and patient-centric innovation
resonates deeply with me,&#148; said Dr.&nbsp;Milligan. &#147;I am honored to join this accomplished team of leaders and eager to collaborate in their goal to drive meaningful advancements in IBD treatment toward improving lives.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Milligan is being appointed as a successor to Russell Cox, whose Board term ended effective May&nbsp;13, 2024. We express our gratitude for
Russell&#146;s dedicated service as the Chairman of the Board. Jeffrey Albers, current member of the Board, has been appointed Chairman in connection with Russell&#146;s departure. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Spyre Therapeutics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Spyre Therapeutics is a
biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) products by combining <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> antibody engineering, rational therapeutic
combinations, and precision medicine approaches. Spyre&#146;s pipeline includes extended half-life antibodies targeting &#945;4<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>7, TL1A, and <FONT STYLE="white-space:nowrap">IL-23.</FONT> For more
information, visit Spyre&#146;s website at www.spyre.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Follow Spyre Therapeutics on social media: @<U>spyretx</U> and <U>LinkedIn</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g839821dsp17.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain statements in this press release, other than purely historical information, may constitute &#147;forward-looking statements&#148; within the meaning of
the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, concerning Spyre and other matters. These forward-looking statements include, but are not
limited to, express or implied statements relating to Spyre&#146;s management team&#146;s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, Spyre&#146;s ability to achieve the expected
benefits or opportunities with respect to its pipeline of product candidates such as potential improved dosing regimens over approved product candidates, Spyre&#146;s preclinical and future clinical development activities, and the potential
therapeutic benefits and economic value of Spyre&#146;s product candidates. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are
forward-looking statements. The words &#147;opportunity,&#148; &#147;potential,&#148; &#147;milestones,&#148; &#147;pipeline,&#148; &#147;can,&#148; &#147;goal,&#148; &#147;aim,&#148; &#147;strategy,&#148; &#147;target,&#148; &#147;seek,&#148;
&#147;anticipate,&#148; &#147;achieve,&#148; &#147;believe,&#148; &#147;contemplate,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intends,&#148; &#147;may,&#148; &#147;might,&#148; &#147;plan,&#148;
&#147;possible,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;will,&#148; &#147;would&#148; and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements,
but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no
assurance that future developments affecting Spyre will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Spyre&#146;s control) or other assumptions that may
cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited those uncertainties and factors described under the
heading &#147;Risk Factors&#148; and &#147;Note about Forward-Looking Statements&#148; in Spyre&#146;s most recent Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the SEC, as well as discussions of potential risks,
uncertainties, and other important factors included in other filings by Spyre from time to time. Should one or more of these risks or uncertainties materialize, or should any of Spyre&#146;s assumptions prove incorrect, actual results may vary in
material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth therein will be achieved or that any of the
contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by
reference to the cautionary statements herein. Spyre does not undertake or accept any duty to make any updates or revisions to any forward-looking statements. This press release does not purport to summarize all of the conditions, risks and other
attributes of an investment in Spyre. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g839821dsp17.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For Investors : </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Eric McIntyre </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VP of Finance and Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Spyre Therapeutics </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Eric.mcintyre@spyre.com </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For Media : </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Peg Rusconi </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Peg.rusconi@vergescientific.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>syre-20240513.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 5/15/2024 2:28:07 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2023"
  xmlns:syre="http://spyre.com/20240513"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://spyre.com/20240513"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" namespace="http://xbrl.sec.gov/naics/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="syre-20240513_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="syre-20240513_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://spyre.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>syre-20240513_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 5/15/2024 2:28:07 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Three</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Three</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>syre-20240513_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 5/15/2024 2:28:07 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://spyre.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="syre-20240513.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://spyre.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine3" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="47.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g839821dsp17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g839821dsp17.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  G * # 2(  A$! Q$!_\0
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MM0>5_P (?_PBW]F^1SN^V_:O/\S=_P !V[??/:BBO%A.4;\O70_,CQOXN_\
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7M@ ;FQDX'4T45$J\Y05-[*]OF%NI_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139652491851504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 13, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001636282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 13,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SPYRE THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-4312787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">221 Crescent Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Building 23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Suite 105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Waltham<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">651-5940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, $0.0001 Par Value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SYRE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MFULC]#2:WX]^QYA*;V<7>?LD$GIMH_0;*)B-3;V$QY6O<S6"9S/,/?EJ8+_
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MTG1X#SY['R73>RHY_U=3_ 102P,$%     @ &CVO6)>*NQS     $P(   L
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( !H]KUBNCX)/E@0  &82   8
M          " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    "  :/:]8GZ ;\+$"  #B#   #0              @ ':#   >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( !H]KUB7BKL<P    !,"   +
M  "  ;8/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( !H]KU@<.&7J/P$  #P"
M   /              "  9\0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M"  :/:]8)!Z;HJT   #X 0  &@              @ $+$@  >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  :/:]899!YDAD!  #/ P
M$P              @ 'P$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
.."0 ) #X"   Z%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>25</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d839821d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d839821d8k.htm">d839821d8k.htm</File>
    <File>syre-20240513.xsd</File>
    <File>syre-20240513_lab.xml</File>
    <File>syre-20240513_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d839821d8k.htm": {
   "nsprefix": "syre",
   "nsuri": "http://spyre.com/20240513",
   "dts": {
    "inline": {
     "local": [
      "d839821d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "syre-20240513.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "syre-20240513_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "syre-20240513_pre.xml"
     ]
    }
   },
   "keyStandard": 25,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 26,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 25
   },
   "report": {
    "R1": {
     "role": "http://spyre.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2024-05-13_to_2024-05-13",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d839821d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2024-05-13_to_2024-05-13",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d839821d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://spyre.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://spyre.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://spyre.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://spyre.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://spyre.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://spyre.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://spyre.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://spyre.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "terseLabel": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://spyre.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://spyre.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://spyre.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://spyre.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://spyre.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://spyre.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://spyre.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://spyre.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://spyre.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://spyre.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://spyre.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://spyre.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://spyre.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://spyre.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://spyre.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://spyre.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://spyre.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001193125-24-138893-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-138893-xbrl.zip
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MWRJ3S)>B0PO%J>+M,>@',+> >]$HP\6&%:1/,S)X#>Q3L';!VFNS-CH#G#!
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MVB,/P?*U#+7D\KCSVH?<DL9GODX/O.'P5$B9 ?XRN6.!]PN\7^#] N\7>+_
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M7,>C<C1G:_;PJBP>>&*4OYVGU3*W\W@;7<>S[%J"K=/V5E[[G-ZL!2PN+U1
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M6C2/!:1;0U;@%YD,Z;MV:W=\@^2.I<C J60T^QKQ!;!G2N8]F<!8$"["6 T
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MJ1A*!D_+O,DO69.Y'/PXKO!?W+\F,[:#@]TX&?O7H[JB9K H75*:^*^EZOI
M>Z,:)]].9W.U0%+VHS&8A>TWV.&5\6C-%N HTX.YBRI9TIQ84U@;*U;TS7-O
MZV ]!P=]4TXB@N PWR8M\5<)],5V<7Z[I0/]I7!Y#6<B>:S77E4>*_D2>WAU
M-^U3Y(,:])].[!H%6-E45MW58Z2 7OQ54T /Q!E/:M6Q?OZA,X*(_$8,>Y>=
M4?_JO1@-L/='G TZPW/LL#CO#WO=T6#X.-9^7?W6%+?$-86!IGS+1@7[GXO
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M.<><9^G9857(XM&8+,<Q @.0*QUVF->L<"!&L@R0J$HBX2JZ-0V],@K=5LZ
M]E=);&7P\QFY3&7O)AI_ I:SP68H>4/\(M('/4[R3RB$BY/<=7^<(&T*-@Y/
MPXH[M&%(-(KN*(E(H*=)#.P'!C#.YBJC7, "J[ YG\Y?)5XF4? @'K+'QZ.=
MC5(*8TXY(5W#0IZE8ZZ$:4KO;-EQ1GE#G;IJM[Y'XG!#7FAC3HB%M9X8(BHW
MYPDWYX(H+T#9I%L^5X&Z_+ZYUTI3V<F/-_B4GGCF/V=D2%=V&'@@[2UIB$R7
MK+AVB"$'?$\=1F!0 .9",JQV>$6#P0?VU&<$83:CSG1?N_]$^6=C#07YOO(.
M\QEX"(1#?XF5=0I=G-09)OE1=(J(D$81[.K.,ZLM_040"%%?/WON@SV?EE S
MD1T#1?<@T*&+K*"BBX]ME53=XVUBSI.*?/ 5-Q"7S&\?EWU8FJ C%C'Y)4>*
M&D?==N'C0PP*V':5/1MI@2_IU@P'6U7TE+L.0U.]1FMB=NC:EM)F8$H'-UHQ
M&U2'S>EN#M<&<@8'/@4Z.V0:*QBLDG*K(,N*,:@I-F"4A' !;+=V@)#5[S8P
MZNZXLGINNU*6\R K<Q].LNXJV5'L]/8S>"67<5E>8Y7:;@$+XR"@O1GR*!;W
MS2J+RQ+RR93@'CB5XNGJ%TT/XA'@!3I(.(U+7GVB&U/(7-3YK(G]Z\JAHBFW
MU(Y$)\LP5E>64-GNIJS&*7RZS708E=5++&^Z(-<UFI.8BZ*2TZH=)VFI,/U&
M/C9=(.4\FVSK<KFDY%8R!C8? [B/L.%I.A.$%=9KX"8E:3'WC"M"+1MH[GV(
M"( $9C:F'+@V]B"'N[6:=V3<L(;<"@5<\)K4_1X0(N)WRRZ?XQ:3OB"#QAIC
MD^>;EYFV%?&,3<64+UK@[7TG-F'$^HH/-&SEB3IM".7-*=_3-WV,0W,_KM(R
MGY 5@2G.4%?GCE??Z"S%&#GI/B88A)XPZM(Q#382N[:48;2P/2JTCUF1IRN1
M]8]M!8R.G@_>O>MW>T-QV>^<]2_[H]^?_ESCI6UQ1'Q>FIO"G/J8;BXM0.F
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MS$5J"E,#RQ>4(@2?AM3+U,@K;(.W:KQFH12J/<=X;+),1@$0^&FE@0J&RBV
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MWQPQ;^;9:=WR%5!+ 0(4 Q0    ( !H]KUCH^,Y4T2(  %(% 0 .
M      "  0    !D.#,Y.#(Q9#AK+FAT;5!+ 0(4 Q0    ( !H]KUAU.345
MX08  'P7   0              "  ?TB  !D.#,Y.#(Q9&5X,S$N:'1M4$L!
M A0#%     @ &CVO6.\W9CE!&@  )'8  !               ( !#"H  &0X
M,SDX,C%D97@S,BYH=&U02P$"% ,4    "  :/:]8+6Y(@)4-  "L*@  $0
M            @ %[1   9#@S.3@R,61E>#DY,2YH=&U02P$"% ,4    "  :
M/:]8U.QMVS@#   W"P  $0              @ $_4@  <WER92TR,#(T,#4Q
M,RYX<V102P$"% ,4    "  :/:]8*E\(9,\&  "E3   %0
M@ &F50  <WER92TR,#(T,#4Q,U]L86(N>&UL4$L! A0#%     @ &CVO6 Z:
MF5OK!   M"\  !4              ( !J%P  '-Y<F4M,C R-# U,3-?<')E
:+GAM;%!+!08     !P ' +P!  #&80     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>d839821d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="syre-20240513.xsd" xlink:type="simple"/>
    <context id="duration_2024-05-13_to_2024-05-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2024-05-13</startDate>
            <endDate>2024-05-13</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-657">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2024-05-13_to_2024-05-13"
      id="Hidden_dei_EntityCentralIndexKey">0001636282</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="duration_2024-05-13_to_2024-05-13"
      id="Hidden_dei_CurrentFiscalYearEndDate_duration_2024-05-13_to_2024-05-13">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-669">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-670">2024-05-13</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-671">SPYRE THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-672">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-673">001-37722</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-674">46-4312787</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-675">221 Crescent Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-676">Building 23</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-677">Suite 105</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-678">Waltham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-679">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-680">02453</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-681">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-682">651-5940</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-683">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-684">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-685">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-686">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-687">Common stock, $0.0001 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-688">SYRE</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-689">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2024-05-13_to_2024-05-13" id="ixv-690">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
